Argitalpenak (133) SEGUNDO GONZALEZ RODRIGUEZ argitalpenak

2023

  1. BTLA dysregulation correlates with poor outcome and diminished T cell-mediated antitumor responses in chronic lymphocytic leukemia

    Cancer Immunology, Immunotherapy, Vol. 72, Núm. 7, pp. 2529-2539

  2. Beyond the anti-PD-1/PD-L1 era: promising role of the BTLA/HVEM axis as a future target for cancer immunotherapy

    Molecular Cancer, Vol. 22, Núm. 1

  3. Chemo-Immunotherapy: A New Trend in Cancer Treatment

    Cancers, Vol. 15, Núm. 11

  4. Immunoglobulin-like transcript 2 blockade restores antitumor immune responses in glioblastoma

    Cancer Science, Vol. 114, Núm. 1, pp. 48-62

2022

  1. Cystatin C-Based Equations Detect Hidden Kidney Disease and Poor Prognosis in Newly Diagnosed Patients with Multiple Myeloma

    Advances in Hematology, Vol. 2022

  2. RICORS2040: The need for collaborative research in chronic kidney disease

    Clinical Kidney Journal, Vol. 15, Núm. 3, pp. 372-387

  3. The Emerging Role of NK Cells in Immune Checkpoint Blockade

    Cancers

2021

  1. Btla/hvem axis induces nk cell immunosuppression and poor outcome in chronic lymphocytic leukemia

    Cancers, Vol. 13, Núm. 8

  2. Checkpoint inhibition in the fight against cancer: NK cells have some to say in it

    Successes and Challenges of NK Immunotherapy: Breaking Tolerance to Cancer Resistance (Elsevier), pp. 267-304

  3. Lag‐3 blockade with relatlimab (Bms‐986016) restores anti‐leukemic responses in chronic lymphocytic leukemia

    Cancers, Vol. 13, Núm. 9

2020

  1. A cytofluorimetric assay to evaluate intracellular cytokine production by NK cells

    Methods in Enzymology (Academic Press Inc.), pp. 343-355

  2. Daratumumab is a safe and effective rescue therapy for multiple myeloma patients who relapse after allo-HSCT

    Bone Marrow Transplantation

  3. Driver mutations and single copy number abnormalities identify binet stage a patients with chronic lymphocytic leukemia with aggressive progression

    Journal of Clinical Medicine, Vol. 9, Núm. 11, pp. 1-8

  4. Evaluation of NK cell cytotoxic activity against malignant cells by the calcein assay

    Methods in Enzymology (Academic Press Inc.), pp. 483-495

  5. Expression of CD47 antigen in Reed–Sternberg cells as a new potential biomarker for classical Hodgkin lymphoma

    Clinical and Translational Oncology, Vol. 22, Núm. 5, pp. 782-785

  6. Lectin-like transcript 1 (LLT1) checkpoint: A novel independent prognostic factor in HPV-negative oropharyngeal squamous cell carcinoma

    Biomedicines, Vol. 8, Núm. 12, pp. 1-14

  7. Mechanisms of apoptosis resistance to NK cell-mediated cytotoxicity in cancer

    International Journal of Molecular Sciences, Vol. 21, Núm. 10

  8. Mechanisms of resistance to NK cell immunotherapy

    Cancers, Vol. 12, Núm. 4

  9. Selective and Potent CDK8/19 Inhibitors Enhance NK-Cell Activity and Promote Tumor Surveillance

    Molecular cancer therapeutics, Vol. 19, Núm. 4, pp. 1018-1030

2019

  1. A flow cytometric NK cell-mediated cytotoxicity assay to evaluate anticancer immune responses In vitro

    Methods in Molecular Biology (Humana Press Inc.), pp. 131-139